🚀 VC round data is live in beta, check it out!
Knight Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Knight Therapeutics and similar public comparables like Immix Biopharma, Absci, Zura Bio, ADC Therapeutics and more.
Knight Therapeutics Overview
About Knight Therapeutics
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.
Founded
2013
HQ
Employees
745
Website
Financials (LTM)
EV
$535M
Knight Therapeutics Financials
Knight Therapeutics reported last 12-month revenue of $337M and EBITDA of $54M.
In the same LTM period, Knight Therapeutics generated $153M in gross profit, $54M in EBITDA, and $613K in net income.
Revenue (LTM)
Knight Therapeutics P&L
In the most recent fiscal year, Knight Therapeutics reported revenue of $329M and EBITDA of $53M.
Knight Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $337M | XXX | $329M | XXX | XXX | XXX |
| Gross Profit | $153M | XXX | $146M | XXX | XXX | XXX |
| Gross Margin | 45% | XXX | 44% | XXX | XXX | XXX |
| EBITDA | $54M | XXX | $53M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $613K | XXX | ($4M) | XXX | XXX | XXX |
| Net Margin | 0% | XXX | (1%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Knight Therapeutics Stock Performance
Knight Therapeutics has current market cap of $548M, and enterprise value of $535M.
Market Cap Evolution
Knight Therapeutics' stock price is $5.58.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $535M | $548M | -0.0% | XXX | XXX | XXX | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKnight Therapeutics Valuation Multiples
Knight Therapeutics trades at 1.6x EV/Revenue multiple, and 10.0x EV/EBITDA.
EV / Revenue (LTM)
Knight Therapeutics Financial Valuation Multiples
As of April 18, 2026, Knight Therapeutics has market cap of $548M and EV of $535M.
Equity research analysts estimate Knight Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Knight Therapeutics has a P/E ratio of 893.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $548M | XXX | $548M | XXX | XXX | XXX |
| EV (current) | $535M | XXX | $535M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 10.0x | XXX | 10.0x | XXX | XXX | XXX |
| EV/EBIT | 26.7x | XXX | 34.0x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | 3.7x | XXX | XXX | XXX |
| P/E | 893.6x | XXX | (139.8x) | XXX | XXX | XXX |
| EV/FCF | 20.1x | XXX | 20.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Knight Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Knight Therapeutics Margins & Growth Rates
Knight Therapeutics' revenue in the last 12 month grew by 8%.
Knight Therapeutics' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Knight Therapeutics' rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Knight Therapeutics' rule of X is 39% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Knight Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 3% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 16% | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | 12% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Knight Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Knight Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Immix Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Absci | XXX | XXX | XXX | XXX | XXX | XXX |
| Zura Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| ADC Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Upstream Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Knight Therapeutics M&A Activity
Knight Therapeutics acquired XXX companies to date.
Last acquisition by Knight Therapeutics was on XXXXXXXX, XXXXX. Knight Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Knight Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKnight Therapeutics Investment Activity
Knight Therapeutics invested in XXX companies to date.
Knight Therapeutics made its latest investment on XXXXXXXX, XXXXX. Knight Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Knight Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Knight Therapeutics
| When was Knight Therapeutics founded? | Knight Therapeutics was founded in 2013. |
| Where is Knight Therapeutics headquartered? | Knight Therapeutics is headquartered in Canada. |
| How many employees does Knight Therapeutics have? | As of today, Knight Therapeutics has over 745 employees. |
| Who is the CEO of Knight Therapeutics? | Knight Therapeutics' CEO is Samira Sakhia. |
| Is Knight Therapeutics publicly listed? | Yes, Knight Therapeutics is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Knight Therapeutics? | Knight Therapeutics trades under GUD ticker. |
| When did Knight Therapeutics go public? | Knight Therapeutics went public in 2014. |
| Who are competitors of Knight Therapeutics? | Knight Therapeutics main competitors are Immix Biopharma, Absci, Zura Bio, ADC Therapeutics. |
| What is the current market cap of Knight Therapeutics? | Knight Therapeutics' current market cap is $548M. |
| What is the current revenue of Knight Therapeutics? | Knight Therapeutics' last 12 months revenue is $337M. |
| What is the current revenue growth of Knight Therapeutics? | Knight Therapeutics revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Knight Therapeutics? | Current revenue multiple of Knight Therapeutics is 1.6x. |
| Is Knight Therapeutics profitable? | Yes, Knight Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Knight Therapeutics? | Knight Therapeutics' last 12 months EBITDA is $54M. |
| What is Knight Therapeutics' EBITDA margin? | Knight Therapeutics' last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Knight Therapeutics? | Current EBITDA multiple of Knight Therapeutics is 10.0x. |
| What is the current FCF of Knight Therapeutics? | Knight Therapeutics' last 12 months FCF is $27M. |
| What is Knight Therapeutics' FCF margin? | Knight Therapeutics' last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Knight Therapeutics? | Current FCF multiple of Knight Therapeutics is 20.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.